Integer Holdings Reports Q1 2025: Sales Up 7.3% Despite Significant Net Loss and Debt Expenses

Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing company focused on enhancing patients’ lives through innovative products. The following summarizes the latest financial performance and key insights derived from its income statement for the first quarter ending March 28, 2025.

Income Statement Overview (Q1 2025):

• Sales: $437.4 million, an increase of 7.3% from $407.8 million in Q1 2024.
• Cost of Sales: $317.1 million, up from $299.5 million, reflecting a 5.9% increase.
• Gross Profit: $120.3 million, improving from $108.3 million, marking an 11.1% increase.
• Operating Expenses: Rose slightly to $70.8 million from $69.6 million, primarily due to higher SG&A costs.
• Operating Income: $49.6 million, up 28.0% from $38.7 million.
• Interest Expense: Increased to $14.8 million from $14.0 million.
• Other Loss: Recorded at $47.9 million, significantly higher due to $46.7 million related to debt conversion inducements.
• Net Income (Loss): Loss of $22.5 million compared to income of $20.6 million in Q1 2024, heavily influenced by the $47.9 million loss and tax provisions.
• Earnings Per Share: Basic and diluted loss per share was $(0.66), a decline from earnings of $0.59 in 2024.

Key Positive Aspects:

• Strong sales performance driven by demand and new product introductions.
• Improved gross profit and gross margin, which is an indicator of better efficiency and pricing power.
• Operating expenses as a percentage of sales have decreased, indicating better expense management relative to revenue growth.

Negative Aspects:

• Reported a significant loss primarily due to unusual expenses related to debt conversion.
• Net income was negatively impacted by high interest and other loss expenses, leading to a loss from operations.
• Fluctuations in foreign exchange rates continued to influence profitability, particularly in overseas markets.

Other Notable Statistics:

• Current Ratio: Increased to 3.40 from 2.95, indicating improved short-term financial health.
• Long-term Debt: Total outstanding debt was $1,235.2 million as of March 28, 2025.
• Acquisition of Precision Coating and VSi Parylene increased capability and product offerings.

Integer Holdings' performance shows a blend of growth in sales and operational efficiencies tempered by significant nonrecurring expenses, notably related to its financial strategies, which may influence future profit potential. Continued focus on managing costs, leveraging recent acquisitions, and optimizing product lines will be critical in navigating upcoming challenges.